Zhitong Finance App News, Baiyunshan (00874) issued an announcement. Recently, the company's branch Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory received the “Drug Registration Certificate” for sorafenib toluene sulfonate tablets approved and issued by the State Drug Administration.

This time, Baiyunshan Pharmaceutical General Factory obtained the “Drug Registration Certificate” for sorafenib toluene sulfonate tablets, which has enriched the variety of anti-tumor drugs and is conducive to improving the company's product layout in the field of cancer treatment. Baiyunshan Pharmaceutical General Plant will carry out production in accordance with relevant requirements and market demand.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.